Valuation dashboard for RenovoRx, Inc. (RNXT) with P/E N/A, P/B 8.16, EV/EBITDA -8.01 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc.
Analysis Summary
Trailing-twelve-month margins: gross margin 84.4%, operating margin -6.8%, net margin -6.2%.
At the current price of $1.55, RNXT has negative trailing earnings (P/E not meaningful) and an ROE of -145.63%. Market capitalisation stands at $70M.
Balance sheet quality for RNXT: current ratio of 4.0. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 8.16 |
| EV / EBITDA | -8.01 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| RNXT | RenovoRx, Inc. | $70M | 8.16 | -145.6% | |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $1.55 |
| Market Cap | $70M |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -145.63% |
| Return on Invested Capital | -139.74% |
| Return on Assets | -107.09% |
| Gross Margin | 84.41% |
| Operating Margin | -678.04% |
| Net Margin | -621.71% |
Related companies: ANVS · BCAB · CALC · CELU · ELUT · LTRN · MAIA
Explore sector: Healthcare · Biotechnology
More sections of RNXT: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks